WSGR logoWSGR logo
Moonkyoung Um
Associate
Patents and Innovations
Boston

D617-598-7869

Download vCard
Open PDF

Dr. Moonkyoung Um is an associate in the Boston office of Wilson Sonsini Goodrich & Rosati, where she is a member of the firm’s patents and innovations practice.  Her practice focuses on patent prosecution, due diligence matters, and patent portfolio management for clients in the fields of life sciences, biotechnologies, small molecules, pharmaceuticals, diagnostics, health information technologies, and medical devices.

Moonkyoung obtained her Ph.D. degree from the Department of Biological Sciences at Columbia University and received her postdoctoral training at the Whitehead Institute for Biomedical Research under the guidance of Dr. Harvey F. Lodish. After her postdoctoral training, she continued her scientific career at the Boston Biomedical Research Institute as a principal investigator and at Boston Children’s Hospital as a research scientist. Through her decades-long career in science, Moonkyoung acquired broad-based experience in the fields of life sciences, including biochemistry, cell biology, molecular biology, mouse genetics, yeast genetics, cancer biology, immunology, neurobiology, metabolic disorders, cardiovascular diseases, and neurological diseases, as well as chemistry and pharmaceutical sciences. 

Experience

Dr. Moonkyoung Um is an associate in the Boston office of Wilson Sonsini Goodrich & Rosati, where she is a member of the firm’s patents and innovations practice.  Her practice focuses on patent prosecution, due diligence matters, and patent portfolio management for clients in the fields of life sciences, biotechnologies, small molecules, pharmaceuticals, diagnostics, health information technologies, and medical devices.

Moonkyoung obtained her Ph.D. degree from the Department of Biological Sciences at Columbia University and received her postdoctoral training at the Whitehead Institute for Biomedical Research under the guidance of Dr. Harvey F. Lodish. After her postdoctoral training, she continued her scientific career at the Boston Biomedical Research Institute as a principal investigator and at Boston Children’s Hospital as a research scientist. Through her decades-long career in science, Moonkyoung acquired broad-based experience in the fields of life sciences, including biochemistry, cell biology, molecular biology, mouse genetics, yeast genetics, cancer biology, immunology, neurobiology, metabolic disorders, cardiovascular diseases, and neurological diseases, as well as chemistry and pharmaceutical sciences. 

Focus Areas
Recent Insights
Client Highlights
Wilson Sonsini Advises Janux Therapeutics on Patent Matters Related to License Agreement with Bristol Myers Squibb
On January 22, 2026, Janux Therapeutics (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), and Tumor Activated Immunomodulator (TRACIr) platforms, announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb. Under the terms of the agreement, the companies will develop a tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Wilson Sonsini Goodrich & Rosati advised Janux on patent matters related to the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises Marengo Therapeutics on Patent Matters Related to Strategic Partnership with Ipsen
On August 1, 2022, Ipsen and Marengo Therapeutics announced a strategic partnership to advance two of Marengo’s preclinical STAR platform-generated candidates into the clinic. The collaboration will leverage Marengo’s proprietary R&D expertise of a novel mechanism of T cell activation with Ipsen’s global oncology footprint for clinical development and commercialization. Under the terms of the agreement, Ipsen will make an upfront payment of $45 million, together with potential payments up to a total of $1.592 billion if all milestones are met in addition to tiered sales royalty payments. Marengo will lead the preclinical development efforts and will expense related costs until the submission of an Investigational New Drug (IND) application to the U.S. FDA. Ipsen will assume responsibilities for clinical development and commercialization.
Learn More
View All
WSGR logo
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.